Investigation of the Effect of Fasting Duration and Temporary Withholding of GLP-1 RAs on Retained Gastric Contents in Participants Treated With s.c. Liraglutide, Oral Semaglutide or s.c. Semaglutide
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• \- On maintenance treatment with either liraglutide 3.0 milligram (mg) for at least 5 days, oral semaglutide 25 mg for at least 5 weeks or semaglutide 2.4 mg for at least 5 weeks prior to screening.
Locations
United States
California
Altasciences Clinical LA, Inc.
RECRUITING
Cypress
Contact Information
Primary
Novo Nordisk
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Time Frame
Start Date: 2025-11-07
Estimated Completion Date: 2026-07-17
Participants
Target number of participants: 75
Treatments
Experimental: Liraglutide
Participants will receive liraglutide subcutaneously.
Experimental: Oral semaglutide
Participants will receive semaglutide orally.
Experimental: Semaglutide
Participants will receive semaglutide subcutaneously.
Related Therapeutic Areas
Sponsors
Leads: Novo Nordisk A/S